
    
      This will be a multicenter, double-blind, randomized, placebo-controlled study in subjects
      with mild to moderate Alzheimer's disease. The study will comprise separate single dose
      ascending (SAD) and multiple dose ascending (MAD) parts designed to allow the MAD part to be
      initiated while the SAD part is ongoing.
    
  